HIV Infections Clinical Trial
Official title:
A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region
This study will determine the prevalence of HIV-related neurological disorders in the countries of the Asia-Pacific Region.
This a cross-sectional study to determine the prevalence of HIV-related Neurological
Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country
site for a period of 2-3 weeks and work with local investigators. Outpatients will be
evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and
HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only
for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis,
cryptococcal meningitis, lymphoma, PML and CMV encephalitis.
The Primary outcomes are:
1. To determine the prevalence of HIV-related neurocognitive impairment and ADC at the
APNAC-10 sites
2. To determine the prevalence of symptomatic peripheral sensory neuropathy at the
APNAC-10 sites
3. To determine the prevalence of central nervous system opportunistic infections and
tumours at the APNAC-10 sites
The secondary outcomes are:
To determine the degree of cognitive impairment in patients presenting with HIV-related
cognitive impairment at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS
defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive
impairment and ADC at the APNAC-10 sites
- To compare the prevalence of HIV-related neurocognitive impairment and ADC at the
APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed
countries
- To compare the prevalence of HIV-related neurocognitive impairment and ADC between the
APNAC-10 sites
- To describe the severity of symptoms of patients presenting with symptomatic peripheral
sensory neuropathy at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of
patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10
sites
- To determine what proportion of symptomatic peripheral sensory neuropathy may be
ascribed to HIV alone, to the use of nucleoside analogues
- To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10
sites to the published pre-HAART prevalence of these conditions in developed countries
- To compare the prevalence of symptomatic peripheral sensory neuropathy between the
APNAC-10 sites
- To determine the prevalence of asymptomatic peripheral neuropathy
- To describe the presenting symptoms and signs of patients presenting with CNS OIs and
tumours at the APNAC-10 sites
- To describe the neuroradiological findings of patients presenting with CNS OIs and
tumours at the APNAC-10 sites
- To determine the serological, culture and other diagnostic test results of patients
presenting with CNS OIs and tumours at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting
with CNS OIs and tumours at the APNAC-10 sites
- To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published
pre-HAART prevalence of these conditions in developed countries
- To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites
;
Observational Model: Natural History, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |